A real world, retrospective study of RBX2660 in patients who had at least one CDI episode with or without co-occurring IBD
Latest Information Update: 01 Nov 2021
At a glance
- Drugs RBX 2660 (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- 01 Nov 2021 New trial record
- 25 Oct 2021 Results published in the Ferring Pharmaceuticals Media Release
- 25 Oct 2021 According to Ferring Pharmaceuticals media release, data of this study presented at the American College of Gastroenterology 2021 annual congress.